Accolate Side Effects
Generic name: zafirlukast
Note: This document contains side effect information about zafirlukast. Some of the dosage forms listed on this page may not apply to the brand name Accolate.
Some side effects of Accolate may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to zafirlukast: oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking zafirlukast (the active ingredient contained in Accolate) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
worsening asthma symptoms;
new or worsening cough, fever, trouble breathing;
mood or behavior changes, anxiety, depression, sleep problems (insomnia);
skin rash, bruising, severe tingling, numbness, pain, muscle weakness; or
nausea, pain in your upper stomach, loss of appetite, flu symptoms, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects of zafirlukast may include:
diarrhea, stomach pain;
muscle pain; or
sore throat, cold symptoms.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to zafirlukast: oral tablet
Nervous system side effects have included headache, asthenia, somnolence, dizziness, fever, insomnia, and pain.
A 47-year-old man with persistent asthma developed sinus congestion, cough, malaise, arthralgia, a progressive rash over his trunk and extremities, and fever within one month of reinitiating zafirlukast (the active ingredient contained in Accolate) therapy. Prior to the development of these symptoms, the patient had been receiving inhaled steroids in combination with zafirlukast therapy. A skin eruption was observed on his face, arms, and trunk. A chest film showed basilar reticulonodular infiltrates, and laboratory findings revealed a positive titer for rheumatoid factor, a blood eosinophil count of 4,350 and an elevated total IgE level (851 intl units/L). The patient's prior medications were discontinued, and he was treated with intravenous hydrocortisone, acyclovir, ceftriaxone, and erythromycin. The patient demonstrated rapid improvement of all signs and symptoms following initiation of hydrocortisone. A causal relationship between zafirlukast therapy and the development of systemic vasculitis was suspected.
Following nearly two months of zafirlukast therapy, a 53-year-old female with a history of asthma and chronic sinusitis developed arthralgias involving her knees, wrists, shoulder and joints. She further developed amaurosis fugax and a hemorrhagic, maculopapular eruption on her elbows and fingers. Her chest film showed multiple pulmonary nodes, and a bronchoscopic lung biopsy revealed eosinophilic infiltrates and granulomas. The patient was initiated on high-dose steroid therapy after which all signs and symptoms promptly resolved. It was believed that this case report represented zafirlukast-induced Churg-Strauss syndrome independent of steroid therapy.
Immunologic side effects have included Churg-Strauss syndrome, also known as allergic granulomatosis, and drug-induced lupus. In addition, increased incidence of infection in patients over the age of 55 has been noted in clinical trials of patients receiving zafirlukast.
Gastrointestinal side effects have included dry mouth, nausea, diarrhea, abdominal pain, vomiting and dyspepsia.
Musculoskeletal side effects have included arthralgia, myalgia and back pain.
In clinical trials, SGPT elevations were comparable between treatment and placebo groups. However, one case of hepatitis and hyperbilirubinemia was observed in a patient receiving zafirlukast (the active ingredient contained in Accolate) 40 mg per day for 100 days.
Hepatic side effects have included elevations of hepatic transaminase levels.
General side effects have included malaise.
Dermatologic side effects have included pruritus.
Psychiatric side effects have included insomnia and depression.
More Accolate resources
- Accolate Prescribing Information (FDA)
- Accolate MedFacts Consumer Leaflet (Wolters Kluwer)
- Accolate Concise Consumer Information (Cerner Multum)
- Accolate Advanced Consumer (Micromedex) - Includes Dosage Information
- Accolate Monograph (AHFS DI)
- Zafirlukast Prescribing Information (FDA)
- Zafirlukast Professional Patient Advice (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.